Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Psychoneuroendocrinology. 2016 Jan 12;66:195–204. doi: 10.1016/j.psyneuen.2016.01.008

Figure 5. Recovery of %TNF-producing monocytes by antagonists of GR (Mifepristone) and of MR (Spironolactone) from ex vivo treatment with three doses of cortisol.

Figure 5

Recovery is calculated as the difference in %TNF+ monocytes between cortisol only (without the blockers) and cortisol with antagonist(s) treatments. Significance was denoted with *p< 0.05 and ***p< 0.001 for the difference between each blocker condition and cortisol only treatment in %TNF-producing monocytes from pairwise comparisons with Bonferroni correction.